Novel Effects of Hormonal Contraceptive Use on the Plasma Proteome

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Josse, Andrea R ^a   Garcia Bailo, Bibiana ^a   Fischer, Karina ^a,b   El Sohemy, Ahmed ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANGIOTENSINOGEN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; APOLIPOPROTEIN L1; BLOOD CLOTTING FACTOR 12A; C REACTIVE PROTEIN; CERULOPLASMIN; COMPLEMENT COMPONENT C1; CONTRACEPTIVE AGENT; ESTROGEN; FETUIN A; GLUCOSE; HEPARIN COFACTOR II; HISTIDINE; KININOGEN; KININOGEN I; LIPID; OROSOMUCOID; PLASMA PROTEIN; PLASMINOGEN; PROGESTERONE; RETINOL BINDING PROTEIN; SERUM AMYLOID P; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; LINEAR REGRESSION ANALYSIS; LIPID METABOLISM; MALE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RISK ASSESSMENT;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PROTEINS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; LIPID METABOLISM; MALE; PRINCIPAL COMPONENT ANALYSIS; PROTEOME; PROTEOMICS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84866333861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045162     Document Type: Article

References (41)

1. Haider Z, D'Souza R, (2009) Non-contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol 23: 249-262.
2. Collins J, Crosignani PG, (2005) Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11: 513-525.
3. Huber JC, Bentz EK, Ott J, Tempfer CB, (2008) Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother 9: 2317-2325.
4. Mendelsohn ME, Karas RH, (2005) Molecular and cellular basis of cardiovascular gender differences. Science 308: 1583-1587.
5. Alonso de Lecinana M, Egido JA, (2006) Estrogens as neuroprotectants against ischemic stroke. Cerebrovasc Dis 21Suppl 2: 48-53.
6. Baillargeon JP, McClish DK, Essah PA, Nestler JE, (2005) Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90: 3863-3870.
7. Khader YS, Rice J, John L, Abueita O, (2003) Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 68: 11-17.
8. Kluft C, (2007) Effects of hormone treatment on hemostasis variables. Climacteric 10Suppl 2: 32-37.
9. Soska V, Fiala J, Nebeska K, Jarkovsky J, Hruba D, (2011) The atherogenic index of plasma is increased by hormonal contraception. Scand J Clin Lab Invest 71: 94-100.
10. Hurwitz BE, Henry N, Goldberg RB, (2009) Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999-2004. Gynecol Endocrinol 25: 441-449.
11. Frempong BA, Ricks M, Sen S, Sumner AE, (2008) Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 93: 2097-2103.
12. Obisesan KA, Adenaike FA, Okunlola MA, Adenaike AA, (2002) Effects of oral contraceptives on total serum proteins, albumin, globulins and cholesterol levels in Ibadan, Nigeria. West Afr J Med 21: 197-199.
13. Du Y, Rosner BM, Knopf H, Schwarz S, Doren M, et al. (2011) Hormonal contraceptive use among adolescent girls in Germany in relation to health behavior and biological cardiovascular risk factors. J Adolesc Health 48: 331-337.
14. Gronich N, Lavi I, Rennert G, (2011) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319-1325.
15. Kwok S, Canoy D, Ashton WD, Lowe GD, Wood D, et al. (2009) Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women's Heart Study (UKWHS). Clin Endocrinol (Oxf) 71: 727-732.
16. Lear SA, Chockalingam A, Kohli S, Richardson CG, Humphries KH (2012) Elevation in Cardiovascular Disease Risk in South Asians Is Mediated by Differences in Visceral Adipose Tissue. Obesity (Silver Spring).
17. Foulds HJ, Bredin SS, Warburton DE, (2012) The relationship between hypertension and obesity across different ethnicities. J Hypertens 30: 359-367.
18. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, et al. (2009) Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 8: 1860-1877.
19. Garcia-Bailo B, Brenner DR, Nielsen D, Lee HJ, Domanski D, et al. (2012) Dietary patterns and ethnicity are associated with distinct plasma proteomic groups. Am J Clin Nutr 95: 352-361.
20. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, et al. (2008) Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 295: L16-22.
21. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, et al. (2009) Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 47: 724-744.
22. Hortin GL, Sviridov D, Anderson NL, (2008) High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 54: 1608-1616.
23. Shen Y, Kim J, Strittmatter EF, Jacobs JM, Camp DG 2nd, et al (2005) Characterization of the human blood plasma proteome. Proteomics 5: 4034-4045.
24. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, et al. (2010) Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 7: e1000286.
25. Salgado FJ, Arias P, Canda-Sánchez A, Nogueira M (2011) Acute Phase Proteins as Biomarkers of Disease: From Bench to Clinical Practice. In: Veas F, editor. Acute Phase Proteins as Early non-Specific Biomarkers of Human and Veterinary Diseases. Rijeka, Croatia: InTech.
26. Anderson L, (2005) Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 563: 23-60.
27. Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, et al. (2009) Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 1: 47.
28. Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, et al. (2009) Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 1: 121.
29. Cahill L, Corey PN, El-Sohemy A, (2009) Vitamin C deficiency in a population of young Canadian adults. Am J Epidemiol 170: 464-471.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
31. Kim J, Mueller C (1978) Factor analysis: statistical methods and practical issues. Newbury Park, CA.: Sage Publications, Inc.
32. DeClercq V, Taylor C, Zahradka P, (2008) Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 8: 228-237.
33. Ekmekci OB, Ekmekci H, (2006) Vitronectin in atherosclerotic disease. Clin Chim Acta 368: 77-83.
34. Folsom AR, (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 86: 366-373.
35. Williams JK, (2004) Rationale for new oral contraceptive dosing. Int J Fertil Womens Med 49: 30-35.
36. Li GH, Arora PD, Chen Y, McCulloch CA, Liu P (2010) Multifunctional roles of gelsolin in health and diseases. Med Res Rev.
37. Fan NJ, Gao CF, Wang CS, Lv JJ, Zhao G, et al. (2012) Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol 26: 41-47.
38. Asleh R, Levy AP, (2005) In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 1: 19-28.
39. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, et al. (2010) Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 12: 293-304.
40. Cahill LE, El-Sohemy A, (2010) Haptoglobin genotype modifies the association between dietary vitamin C and serum ascorbic acid deficiency. Am J Clin Nutr 92: 1494-1500.
41. Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ, (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6: 1045-1056.